During February 2024, a care recipient informed of having known to be HCV RNA positive, but due to his drug use behavior he couldn’t initiate treatment.
The data enumerators provided the care recipient with required pre-treatment counseling and the importance of early diagnosis and treatment. His family supported the pre-treatment test, required by government guidelines, at a private diagnostics center. This was also to enable shorten the waiting time for the pre-treatment test results.
The person initiated his treatment on February 12, with sofosbuvir/daclatasvir for 12 weeks.